TY - JOUR
T1 - The value of tailoring vial sizes to populations and locations
AU - Wedlock, Patrick T.
AU - Mitgang, Elizabeth A.
AU - Haidari, Leila A.
AU - Prosser, Wendy
AU - Brown, Shawn T.
AU - Krudwig, Kirstin
AU - Siegmund, Sheryl S.
AU - DePasse, Jay V.
AU - Bakal, Jennifer
AU - Leonard, Jim
AU - Welling, Joel
AU - Steinglass, Robert
AU - Mwansa, Frances Dien
AU - Phiri, Guissimon
AU - Lee, Bruce Y.
N1 - Funding Information:
This work was supported by the Bill and Melinda Gates Foundation, the Agency for Healthcare Research and Quality (AHRQ) via grant R01HS023317 , USAID System and Complexity Monitoring, Evaluation, Research, and Learning (System and Complexity MERL) via AID-OAA-A-15-00064, National Institute of General Medical Sciences Modeling Infectious Disease Agent Study (MIDAS) Informatics Services Group grant 1U24GM110707 , and the Global Obesity Prevention Center (GOPC) at Johns Hopkins and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Office of the Director, National Institutes of Health (OD) under award number U54HD070725 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Funding Information:
This work was supported by the Bill and Melinda Gates Foundation, the Agency for Healthcare Research and Quality (AHRQ) via grant R01HS023317, USAID System and Complexity Monitoring, Evaluation, Research, and Learning (System and Complexity MERL) via AID-OAA-A-15-00064, National Institute of General Medical Sciences Modeling Infectious Disease Agent Study (MIDAS) Informatics Services Group grant 1U24GM110707, and the Global Obesity Prevention Center (GOPC) at Johns Hopkins and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Office of the Director, National Institutes of Health (OD) under award number U54HD070725. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Publisher Copyright:
© 2018
PY - 2019/1/21
Y1 - 2019/1/21
N2 - Background: Frequently, a country will procure a single vaccine vial size, but the question remains whether tailoring the use of different size vaccine vial presentations based on populations or location characteristics within a single country could provide additional benefits, such as reducing open vial wastage (OVW) or reducing missed vaccination opportunities. Methods: Using the Highly Extensible Resource for Modeling Supply Chains (HERMES) software, we built a simulation model of the Zambia routine vaccine supply chain. At baseline, we distributed 10-dose Measles-Rubella (MR) vials to all locations, and then distributed 5-dose and 1-dose MR vials to (1) all locations, (2) rural districts, (3) rural health facilities, (4) outreach sites, and (5) locations with average MR session sizes <5 and <10 children. We ran sensitivity on each scenario using MR vial opening thresholds of 0% and 50%, i.e. a healthcare worker opens an MR vaccine for any number of children (0%) or if at least half will be used (50%). Results: Replacing 10-dose MR with 5-dose MR vials everywhere led to the largest reduction in MR OVW, saving 573,892 doses (103,161 doses with the 50% vial opening threshold) and improving MR availability by 1% (9%). This scenario, however, increased cold chain utilization and led to a 1% decrease in availability of other vaccines. Tailoring 5-dose MR vials to rural health facilities or based on average session size reduced cold transport constraints, increased total vaccine availability (+1%) and reduced total cost per dose administered (−$0.01) compared to baseline. Conclusions: In Zambia, tailoring 5-dose MR vials to rural health facilities or by average session size results in the highest total vaccine availability compared to all other scenarios (regardless of OVT policy) by reducing open vial wastage without increasing cold chain utilization.
AB - Background: Frequently, a country will procure a single vaccine vial size, but the question remains whether tailoring the use of different size vaccine vial presentations based on populations or location characteristics within a single country could provide additional benefits, such as reducing open vial wastage (OVW) or reducing missed vaccination opportunities. Methods: Using the Highly Extensible Resource for Modeling Supply Chains (HERMES) software, we built a simulation model of the Zambia routine vaccine supply chain. At baseline, we distributed 10-dose Measles-Rubella (MR) vials to all locations, and then distributed 5-dose and 1-dose MR vials to (1) all locations, (2) rural districts, (3) rural health facilities, (4) outreach sites, and (5) locations with average MR session sizes <5 and <10 children. We ran sensitivity on each scenario using MR vial opening thresholds of 0% and 50%, i.e. a healthcare worker opens an MR vaccine for any number of children (0%) or if at least half will be used (50%). Results: Replacing 10-dose MR with 5-dose MR vials everywhere led to the largest reduction in MR OVW, saving 573,892 doses (103,161 doses with the 50% vial opening threshold) and improving MR availability by 1% (9%). This scenario, however, increased cold chain utilization and led to a 1% decrease in availability of other vaccines. Tailoring 5-dose MR vials to rural health facilities or based on average session size reduced cold transport constraints, increased total vaccine availability (+1%) and reduced total cost per dose administered (−$0.01) compared to baseline. Conclusions: In Zambia, tailoring 5-dose MR vials to rural health facilities or by average session size results in the highest total vaccine availability compared to all other scenarios (regardless of OVT policy) by reducing open vial wastage without increasing cold chain utilization.
KW - Measles-rubella
KW - Supply chain logistics
KW - Tailoring
KW - Vial size
UR - http://www.scopus.com/inward/record.url?scp=85058520413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058520413&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2018.12.010
DO - 10.1016/j.vaccine.2018.12.010
M3 - Article
C2 - 30578087
AN - SCOPUS:85058520413
SN - 0264-410X
VL - 37
SP - 637
EP - 644
JO - Vaccine
JF - Vaccine
IS - 4
ER -